Gohibic (Vilobelimab)

Gohibic is investigated for therapeutic use in diseases characterized by excessive activation of the complement system, particularly those involving the C5a fragment. Clinical studies have focused on its potential role in:

• Treatment of severe inflammatory conditions where C5a‑driven pathways are implicated.
• Management of acute respiratory distress syndrome associated with complement activation.
• Adjunct therapy in certain autoimmune disorders with documented C5a involvement.
• Supportive care in sepsis cases where uncontrolled complement activity contributes to organ dysfunction.
• Investigation in rare genetic complement deficiencies as part of clinical trial protocols.

Vilobelimab may be associated with a range of adverse reactions, reflecting its immunomodulatory activity. Reported events are grouped into common and serious categories.

Common

• Mild infusion‑related reactions such as flushing, headache, or nausea.
• Transient elevations in liver enzymes (ALT, AST) without clinical symptoms.
• Low‑grade fever or chills occurring during or shortly after administration.
• Mild fatigue or malaise reported by some patients.

Serious

• Severe hypersensitivity reactions, including anaphylaxis, requiring immediate medical intervention.
• Significant infections such as bacterial sepsis or opportunistic fungal infections.
• Thromboembolic events, including deep vein thrombosis or pulmonary embolism.
• Uncontrolled complement activation leading to organ dysfunction, particularly renal or hepatic injury.

Because Gohibic modulates the complement cascade, certain clinical situations require careful assessment before initiating therapy. Healthcare providers should consider and ensure the following precautions to minimize risk and protect patient safety.

• Screen for active infections before each infusion, as complement inhibition can impair host defense.
• Avoid use in patients with a history of severe allergic reactions to monoclonal antibodies.
• Monitor liver function tests regularly during treatment.
• Assess renal function periodically, especially in patients with pre‑existing kidney disease.
• Use caution in individuals with a known propensity for thrombosis or clotting disorders.
• Pregnancy and lactation status should be evaluated, as safety data are limited.

Vilobelimab may interact with other agents that affect immune function or hemostasis. The following drug interaction considerations are based on its mechanism of complement inhibition in clinical practice.

Avoid

• Concurrent use of other complement inhibitors, as additive suppression may increase infection risk.
• Combination with live vaccines, because immune response may be insufficient.

Use with caution

• Co‑administration of immunosuppressive agents (e.g., corticosteroids, calcineurin inhibitors) may heighten infection susceptibility.
• Concurrent anticoagulants or antiplatelet drugs, due to potential increased bleeding risk.
• Therapies that elevate liver enzymes, as combined hepatotoxicity could occur.